X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   MYLAN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
MYLAN
Dec-14
AJANTA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7203,992-   
Low Rs1,1032,813-   
Sales per share (Unadj.) Rs194.61,366.6-  
Earnings per share (Unadj.) Rs45.2164.6-  
Cash flow per share (Unadj.) Rs50.3265.0-  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0679.3-  
Shares outstanding (eoy) m88.77378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x7.32.5 291.3%   
Avg P/E ratio x31.220.7 151.0%  
P/CF ratio (eoy) x28.112.8 218.6%  
Price / Book Value ratio x10.75.0 213.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,287,436 9.7%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m2,5700-   
Avg. sales/employee Rs ThNM20,683.4-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,491.7-  
INCOME DATA
Net Sales Rs m17,275517,086 3.3%  
Other income Rs m166-3,014 -5.5%   
Total revenues Rs m17,442514,072 3.4%   
Gross profit Rs m5,807128,602 4.5%  
Depreciation Rs m45137,978 1.2%   
Interest Rs m4922,304 0.2%   
Profit before tax Rs m5,47465,306 8.4%   
Minority Interest Rs m0-268 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4602,746 53.2%   
Profit after tax Rs m4,01462,291 6.4%  
Gross profit margin %33.624.9 135.2%  
Effective tax rate %26.74.2 634.2%   
Net profit margin %23.212.0 192.9%  
BALANCE SHEET DATA
Current assets Rs m7,639454,587 1.7%   
Current liabilities Rs m2,715355,396 0.8%   
Net working cap to sales %28.519.2 148.6%  
Current ratio x2.81.3 220.0%  
Inventory Days Days4378 55.4%  
Debtors Days Days79107 73.3%  
Net fixed assets Rs m6,914119,626 5.8%   
Share capital Rs m17718,286 1.0%   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,721257,042 4.6%   
Long term debt Rs m149383,996 0.0%   
Total assets Rs m14,8141,035,343 1.4%  
Interest coverage x112.93.9 2,875.4%   
Debt to equity ratio x01.5 0.8%  
Sales to assets ratio x1.20.5 233.5%   
Return on assets %27.48.2 335.7%  
Return on equity %34.224.2 141.3%  
Return on capital %46.513.6 341.5%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,26467,971 4.8%  
From Investments Rs m-2,093-53,604 3.9%  
From Financial Activity Rs m-1,186-17,910 6.6%  
Net Cashflow Rs m-15-3,543 0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 66.98 Rs / USD

Compare AJANTA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: BIOCON LTD  VENUS REMEDIES  DR. REDDYS LAB  ALKEM LABORATORIES  DISHMAN PHARMA  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - WOCKHARDT LTD. COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS